BTIG Downgrades Apogee Therapeutics to Neutral

Benzinga Newsdesk www.benzinga.com Negative 84.9%

Neg 84.9% Neu 0% Pos 0%

BTIG analyst Julian Harrison downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral.

Comments

No comments yet. Be the first!